Lundbeck LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$46.4M
Doctors Paid
66,563
Transactions
474,600
2024 Total
$4.1M
Payment Breakdown by Category
Royalty/License$19.3M (41.6%)
Food & Beverage$8.5M (18.4%)
Research$6.7M (14.4%)
Consulting$2.0M (4.3%)
Travel$1.0M (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $19.3M | 33 | 41.6% |
| Food and Beverage | $8.5M | 462,340 | 18.4% |
| Honoraria | $7.7M | 4,103 | 16.6% |
| Unspecified | $6.7M | 151 | 14.4% |
| Consulting Fee | $2.0M | 2,164 | 4.3% |
| Travel and Lodging | $1.0M | 4,359 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $658,653 | 14 | 1.4% |
| Grant | $367,200 | 13 | 0.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $124,500 | 3 | 0.3% |
| Charitable Contribution | $52,300 | 32 | 0.1% |
| Education | $6,272 | 1,388 | 0.0% |
Payments by Type
General
$39.8M
474,449 transactions
Research
$6.7M
151 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Preventing Epilepsy using Vigabatrin in Infants with TB Complex (PREVENT Trial), a randomized, double-blind, placebo controlled seizure prevention clinical trial for infants with TSC | $3.5M | 0 | 1 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE | $1.0M | 17 | 102 |
| Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Anew | $1.0M | 0 | 1 |
| N/A | $168,633 | 0 | 5 |
| Effects of L-Dihydoxyphenyserine (L-DOPS, Northera) a central and peripheral norepinephrine agent on locomotion, postural stability (balance), and Fall Reduction in PD | $136,741 | 0 | 1 |
| Evaluation of add-on treatment of adults with refractory localization related epilepsy with clobazam A pilot study | $92,600 | 0 | 1 |
| Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients with Orthostatic Hypotension Feasibility and Effect-Size Finding Study | $77,828 | 0 | 1 |
| Northera Improves Postural Tachycardia Syndrome POTS and Postural Vasovagal Syncope VVS | $77,828 | 0 | 1 |
| Evaluation of Brain Perfusion and Oxygenation in PD patients with Neurogenic Orthostatic Hypotension: 4 Week Comparison of droxidopa versus Placebo | $76,527 | 0 | 1 |
| Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) | $68,215 | 0 | 2 |
| Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine RELIEF | $51,500 | 0 | 5 |
| Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy | $46,000 | 0 | 1 |
| A Retrospective Study Safety and efficacy of Clobazam in Children with Seizures Less Than Two Years of Age | $41,210 | 0 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease | $40,965 | 0 | 1 |
| Safety and efficacy of droxidopa for fatigue in patients with Parkinsonism | $37,637 | 0 | 1 |
| Clinical Diagnosis of Neurogenic Orthostatic Hypotension | $35,122 | 0 | 1 |
| Treatment of Anxiety Comorbid with Epilepsy | $28,760 | 0 | 1 |
| An Open Label Trial of ALD403 Eptinezumab in Chronic Migraine PREVAIL | $24,274 | 0 | 5 |
| Evaluation of ALD403 Eptinezumab in the Prevention of Chronic Migraine PROMISE 2 | $23,657 | 0 | 2 |
| Norepinephrine-targeted therapy for action control in parkinson disease | $15,604 | 0 | 1 |
| Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients with Orthostatic Hypotension: Feasibility and Effect-Size Finding Study | $14,904 | 0 | 1 |
| Effects of Clobazam on sleep and daytime function in patients with epilepsy | $13,057 | 0 | 1 |
| Epilepsy Birth Control Registry - Full Prospective Study | $12,955 | 0 | 1 |
| Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease (droxidopa) | $11,975 | 0 | 1 |
| Assessing Impulsivity and Suicidality in Xenazine | $7,784 | 0 | 1 |
| Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2) | $7,587 | 0 | 2 |
| Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (RESTORE) | $7,000 | 0 | 1 |
| Brain Perfusion & Oxygenation in Parkinsons Disease With NOH | $5,919 | 0 | 1 |
| Norepinephrine-targeted Therapy for Action Control in Parkinson Disease | $3,057 | 0 | 1 |
| Electrophysiological and behavioral characterizations of droxidopa as a potential drug for ADHD | $2,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Roy Elterman, Md, MD | Neurology with Special Qualifications in Child Neurology | Dallas, TX | $9.7M | $0 |
| Dr. William Shields, M.d, M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $9.7M | $0 |
| Brian Olshansky, Md, MD | Internal Medicine | Iowa City, IA | $340,900 | $0 |
| Dr. Sameh Mobarek, M.d, M.D | Internal Medicine | Cary, NC | $272,559 | $0 |
| Dr. Fahd Amjad, Md, MD | Neurology | Washington, DC | $196,437 | $0 |
| Stephen Landy, Md, MD | Neurology | Tupelo, MS | $194,036 | $0 |
| Dr. Salima Brillman, Md, MD | Psychiatry | Sunnyvale, CA | $193,988 | $0 |
| Dr. Chaouki Khoury, Md, Ms, MD, MS | Neurology with Special Qualifications in Child Neurology | Atlanta, GA | $163,186 | $0 |
| Peter Mcallister, M.d, M.D | Neurology | Fairfield, CT | $160,763 | $0 |
| Dr. Stuart Isaacson, Md, MD | Neurology | Boca Raton, FL | $148,785 | $0 |
| Atiya Khan, M.d, M.D | Neurology | Fort Wayne, IN | $139,517 | $0 |
| Barbara Peterlin, Do, DO | Neurology | East Syracuse, NY | $137,678 | $0 |
| Jaclyn Duvall, Md, MD | Neurology | Tulsa, OK | $133,857 | $0 |
| Amit Masih, Md, MD | Behavioral Neurology & Neuropsychiatry | Okemos, MI | $131,464 | $0 |
| Dr. Andrew Blumenfeld, M.d, M.D | Neurology | Los Angeles, CA | $130,966 | $0 |
| Dr. Emad Estemalik, Md, MD | Child & Adolescent Psychiatry | Lakewood, OH | $119,818 | $0 |
| Dr. Michael Gen, M.d, M.D | Interventional Cardiology | Virginia Beach, VA | $118,370 | $0 |
| Wade Cooper, Do, DO | Neurology | Ann Arbor, MI | $116,522 | $0 |
| Jessica Ailani, Md, MD | Neurology | Washington, DC | $114,751 | $0 |
| Dr. Sean Beinart, M.d, M.D | Internal Medicine | Rockville, MD | $103,282 | $0 |
| Nicolas Saikali, Md, MD | Neurology | Amherst, NY | $102,503 | $0 |
| Ramon Gil, Md, MD | Specialist | Port Charlotte, FL | $99,864 | $0 |
| Dr. Cherian Karunapuzha, Md, MD | Neurology | Oklahoma City, OK | $97,067 | $0 |
| Lance Kim, Do, DO | Vascular Neurology | Ocala, FL | $92,738 | $0 |
| Dr. Amaal Starling, M.d, M.D | Neurology | Scottsdale, AZ | $89,786 | $0 |
About Lundbeck LLC
Lundbeck LLC has made $46.4M in payments to 66,563 healthcare providers, recorded across 474,600 transactions in the CMS Open Payments database. In 2024, the company paid $4.1M. The top product by payment volume is SABRIL ($22.8M).
Payments were distributed across 306 medical specialties. The top specialty by payment amount is Neurology with Special Qualifications in Child Neurology ($10.2M to 369 doctors).
Payment categories include: Food & Beverage ($8.5M), Consulting ($2.0M), Research ($6.7M), Travel & Lodging ($1.0M), Royalties ($19.3M).
Lundbeck LLC is associated with 5 products in the CMS Open Payments database, including SABRIL, NORTHERA, and ONFI.